亿腾景昂药业（EOC Pharma）是一家专注于引进海外创新药物、在国内同步进行研发、生产和商业化的创新医药公司。公司目前已有7个创新产品研发管线，这些在研产品均具备成为同类最新或最好药物的潜力。截止目前，公司已获得了4个1类新药临床试验批件并正在国内开展不同阶段的临床试验。公司的管理和顾问团队拥有深厚的国际大型药企研发经验和丰富的医药产业经历。公司在中国泰州医药城建立了生产基地，并在中国北京、上海、香港和美国洛杉矶设有办公室。公司旨在引进具有差异化、适合中国市场的海外创新药物，充分利用合作伙伴的海外临床数据，加速推进创新药物在中国的临床研究，从而实现早日为中国患者提供安全、可靠、高效的创新药物，造福人类。

     EOC Pharma is an integrated biopharmaceutical company that is focused on the manufacturing, development and commercialization of innovative global oncology products in China.  EOC has adopted a licensing model in order to build EOC’s innovative pipeline by plugging our partner’s molecule into EOC’s “core engine” of local manufacturing, clinical development, regulatory filing, and commercialization. The company now has a pipeline of Seven novel products from global biopharmaceutical partners that are potentially first- and best-in-class. Until now, EOC has obtained four Class I innovative drug CTA approvals and initiated clinical studies of four lead products in China. EOC has a team of entrepreneurs and consultants with overseas background that boasts of first-class pharmaceutical R&D expertise as well as rich industry experience. The company owns an 8,000 square meter cGMP manufacturing facility in Taizhou, China Medical City and has offices in Shanghai, Beijing, Hong Kong and Los Angeles.